HS-10370 / Jiangsu Hansoh Pharma - LARVOL DELTA

Efficacy and Safety of HS-10370 Combined With Adebrelimab and Chemotherapy in First-Line Advanced KRAS G12C-Mutated NSCLC (IASLC-WCLC 2026) - P1 | "Methods : Treatment-naïve pts with locally advanced/metastatic non-squamous NSCLC and KRAS G12C mutation received HS-10370 (400 mg or 800 mg) orally once daily, adebrelimab (20 mg/kg) intravenously every 3 weeks (Q3W), and pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC 5 mg/ml/min) intravenously Q3W (4-6 cycles for platinum-based drugs), until disease progression or unacceptable toxicity. Conclusions : HS-10370 in combination with adebrelimab and platinum-based chemotherapy demonstrated a manageable safety profile and promising anti-tumor activity as 1L treatment for advanced NSCLC with KRAS G12C mutation across all PD-L1 expression levels. These findings suggest a longer survival follow-up for RP3D determination and further evaluation in a randomized phase 3 trial."

Clinical • IO biomarker • Metastases • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Neutropenia • Non Small Cell Lung Cancer • Solid Tumor • KRAS

A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=448 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

New P3 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS

Hansoh Pharmaceutical Group…announced that HS-10370 combination regimen has yielded encouraging results in patients with untreated advanced KRAS G12C-mutated NSCLC (Hansoh Pharma Press Release) - "The results were delivered as an oral presentation at the 2026 World Conference on Lung Cancer (WCLC 2026)....The study results showed: Robust Anti-tumor Activity: With median follow-up of 13.6 months, The confirmed ORR was 81.5% and the disease control rate (DCR) was 98.1%. Median PFS has not yet reached, and the 12‑month PFS rate was 78.7%. The combination regimen demonstrated consistent antitumor activity across different PD‑L1 expression subgroups. Notably, patients with PD‑L1 TPS ≥ 50% achieved a confirmed ORR of 93.8% and12‑month PFS rate of 100%. Manageable safety profile: Grade ≥3 treatment-related adverse event (TRAEs) occurred in 80.0% of subjects and there were no treatment-related deaths."

P1 data • Non Small Cell Lung Cancer

Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC) (AACR 2024) - P1/2 | "HS-10370 was well tolerated and showed inspiring antitumor activities in KRAS G12C mutated advanced solid tumors, especially in NSCLC."

Clinical • First-in-human • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

Safety and efficacy of HS-10370 in KRAS G12C-mutated advanced solid tumors: Updated results from phase 1 study (AACR 2025) - P1/2 | "With extended follow-up, HS-10370 continued to demonstrate impressive and durable antitumor activity and was well tolerated in patients with advanced KRAS G12C-positive solid tumor."

Clinical • First-in-human • Metastases • P1 data • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=762 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

New P1 trial • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=350 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Metastases • New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=176 | Recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Monotherapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS

Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=176 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Monotherapy • New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS